We are live on ! Find out more
SGMO

SANGAMO THERAPEUTICS INC

Delisted

SGMO was delisted on the 4th of May, 2026.

122 hedge funds and large institutions have $34.5M invested in SANGAMO THERAPEUTICS INC in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 33 increasing their positions, 33 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 33

4% less call options, than puts

Call options by funds: $1.77M | Put options by funds: $1.84M

5% less funds holding

Funds holding: 128122 (-6)

6.12% less ownership

Funds ownership: 29.51%23.39% (-6.1%)

18% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 28

45% less capital invested

Capital invested by funds: $62.9M → $34.5M (-$28.4M)

Holders
122
Holders Change
-6
Holders Change %
-4.69%
% of All Funds
1.64%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
23
Increased
33
Reduced
33
Closed
28
Calls
$1.77M
Puts
$1.84M
Net Calls
-$75K
Net Calls Change
+$1.41M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$6.15M
WA
2
Wasatch Advisors
Utah
$4.5M -$2.5M -2,362,739 -26%
BlackRock
3
BlackRock
New York
$3.57M +$267K +251,714 +5%
Renaissance Technologies
4
Renaissance Technologies
New York
$2.08M +$88.1K +83,230 +3%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.5M +$75.8K +71,601 +3%
Point72 Asset Management
6
Point72 Asset Management
Connecticut
$1.31M -$289K -272,507 -12%
IC
7
Ikarian Capital
Texas
$1.22M
Susquehanna International Group
8
Susquehanna International Group
Pennsylvania
$1.19M +$1.61M +1,524,637 +535%
Jacobs Levy Equity Management
9
Jacobs Levy Equity Management
New Jersey
$851K +$588K +555,323 +75%
Millennium Management
10
Millennium Management
New York
$769K -$1.66M -1,567,574 -57%
State Street
11
State Street
Massachusetts
$736K -$4.13M -3,896,091 -78%
Charles Schwab
12
Charles Schwab
California
$720K -$43.9K -41,418 -4%
OM
13
Opaleye Management
Massachusetts
$692K +$1.12M +1,055,000 New
GCP
14
GSA Capital Partners
United Kingdom
$634K +$990K +934,649 +2,962%
Goldman Sachs
15
Goldman Sachs
New York
$626K -$690K -651,670 -41%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$590K +$203K +191,700 +27%
Two Sigma Investments
17
Two Sigma Investments
New York
$516K -$239K -225,895 -22%
HighTower Advisors
18
HighTower Advisors
Illinois
$499K +$4.07K +3,840 +0.5%
Morgan Stanley
19
Morgan Stanley
New York
$489K -$1.2M -1,135,500 -60%
Marshall Wace
20
Marshall Wace
United Kingdom
$430K +$333K +314,776 +93%
UBS Group
21
UBS Group
Switzerland
$401K +$293K +276,805 +83%
Fidelity Investments
22
Fidelity Investments
Massachusetts
$369K -$16.2K -15,329 -3%
BFM
23
Boothbay Fund Management
New York
$352K
Invesco
24
Invesco
Georgia
$317K +$232K +219,253 +83%
GCM
25
Graham Capital Management
Connecticut
$283K +$359K +338,591 +363%

SGMO Hedge Fund Activity: Q1 2025 in Review

122 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q1 2025, worth a combined $34.5M — down 45% from $62.9M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of SGMO and 23 opened new positions — a net loss of 5 holders — while 33 trimmed existing stakes and 33 added.

The largest buyer was Susquehanna International Group, adding an estimated $1.61M. The largest seller was State Street, cutting an estimated $4.13M.

  • 122 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q1 2025, down from 128 in Q4 2024.
  • Funds reported $34.5M of SANGAMO THERAPEUTICS INC stock for Q1 2025, down 45% quarter-over-quarter.
  • 23 funds opened new SANGAMO THERAPEUTICS INC positions in Q1 2025 and 28 closed out, a net change of -5 holders.
  • The largest SANGAMO THERAPEUTICS INC buyer in Q1 2025 was Susquehanna International Group, an estimated $1.61M added.
  • The largest SANGAMO THERAPEUTICS INC seller in Q1 2025 was State Street, an estimated $4.13M sold.

Based on aggregated 13F filings for Q1 2025.